Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation

Blood

Volumn 95, Issue 7, 2000, Pages 2434-2439

  Tsukada, Nobuhiro ^b   Akiba, Hisaya ^b   Kobata, Tetsuji ^a   Aizawa, Yoshifusa ^b   Yagita, Hideo ^b   Okumura, Ko ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 4; LIGAND; MONOCLONAL ANTIBODY; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; LETHALITY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECIPIENT; T LYMPHOCYTE;

EID: 0034177891     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.7.2434     Document Type: Article

References (47)

1. Thomas ED. Karnofsky memorial lecture. Marrow transplantation for malignant disease. J Clin Oncol. 1983;1:517.
2. Bortin MM, Rimm AA. Increasing utilization of bone marrow transplantation. Transplantation. 1986;42:229.
3. Herve P, Cahn JY, Beatty PG. Graft-versus-host disease after bone marrow transplantation from donors other than HLA-identical siblings. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkins K, eds. Graft-Versus-Host Disease. New York, NY: Dekker; 1990:425.
4. Wagner JE, Donnenberg AD, Noga SJ, et al. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988;72:1168.
5. Young JW, Papadopoulos EB, Cunningham I, et al. T-cell-depleted allogeneic bone marrow transplantation in adults with nonlymphocytic leukemia in first remission. Blood. 1992;79:3380.
6. Filipovich AH, Vallera D, McGlave P, et al. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease. Transplantation. 1990;50:410.
7. Hale G, Cobbold S, Waldmann H. T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation. 1988;45:753.
8. Soiffer RJ, Fairclough D, Robertson M, et al. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997;89:3039.
9. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120.
10. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated T-cell depletion. Ann Intern Med. 1988;108:806.
11. Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med. 1986;105:20.
12. Herve P, Wijdenes J. Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood. 1990;75:1017.
13. Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation. 1990;50:49.
14. Blaise D, Olive D, Hirn M, et al. Prevention of acute GVHD by in vivo use of anti-interleukin-receptor monoclonal antibody (33B31.1). Bone Marrow Transplant. 1991;8:105.
15. Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;84:1320.
16. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the graft-vs.-host disease. J Exp Med. 1987;166:1280.
17. Speiser DE, Bachmann MF, Frick TW, et al. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol. 1997;158:5185.
18. Hattori K, Hirano T, Ushiyama C, et al. A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice. Blood. 1997;90:542.
19. Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor H antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91:4051.
20. + T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol. 1997;158:29.
21. Durie FH, Aruffo A, Ledbetter J, et al. Antibody to the ligand of CD40, gp39. blocks the occurrence of the acute and chronic forms of graft-versus-host disease. J Clin Invest. 1994;94:1333.
22. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 1996;183:657.
23. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol. 1996;157: 5387.
24. Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 1996;183: 2645.
25. Weinberg AD, Bourdette DN, Sullivan TJ, et al. Selective depletion of myelin-reactive T cells with the anti-OX40 antibody ameliorates autoimmune encephalomyelitis. Nat Med. 1996;2:183.
26. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 1997;89:4652.
27. Durie FH, Fanslow WC, Zappone J, et al. Conversion of chronic graft-versus-host disease to that of the acute phenotype using in vivo administration of an antibody to OX40 [abstract]. FASEB J. 1996;10:1435.
28. Akiba H, Oshima H, Takeda K, et al. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J Immunol. 1999; 162:7058.
29. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol. 1995; 154:2687.
30. Allen RD, Staley TA, Sidman CL. Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol. 1993; 23:333.
31. Krenger W, Ferrara JL. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res. 1996; 15:50.
32. Tanaka J, Imamura M, Kasai M, et al. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease. Bone Marrow Transplant. 1997;19:571.
33. Baum PR, Gayle RB III, Ramsdell F, et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 1994:13:3992.
34. + T cells with homology to tumor necrosis factor. J Exp Wed. 1994; 180:757.
35. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. Expression and function of OX40 ligand on human dendritic cells. J Immunol. 1997;159:3838.
36. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX40/OX-40 ligand interaction in vivo and in vitro leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 1999;162: 1818.
37. Higgins LM, McDonald SAC, Whittle N, Crockett N, Shields JG, McDonald TT. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999;162: 486.
38. Blazer BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood. 1994;83: 3815.
39. Saito K, Azuma M, Hashimoto H, Yagita H, Okumura K. Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute graft-versus-host disease. Eur J Immunol. 1996; 26:3098.
40. Saito K, Sakurai J, Ohta J, et al. Involvement of CD40 ligand-CD40 and CDLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. J Immunol. 1998;160:4225.
41. Flynn S, Toellner KM, Raykundalia, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med. 1998;188:297.
42. 1 model of acute graft versus host disease. Transplantation. 1995;59:890.
43. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155:585.
44. Via CS, Rus V, Gately MK, Finkelman FD. IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J Immunol. 1994;153:4040.
45. Murphy WJ, Welniak LA, Taub DD, et al. Differential effect of the absence of interferon-g and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998;102:1742.
46. Imura A, Hori T, Imada K, et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood. 1997;89:2951.
47. Matsumura Y, Imura A, Hori T, Uchiyama T, Imamura S. Localization of OX40/gp34 in inflammatory skin disease: a clue to elucidate the interaction between activated T cells and endothelial cells in infiltration. Arch Dermatol Res. 1997;289: 653.